Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

被引：0
|
作者：
Dimitrios Pectasides
Vasilios Karavasilis
George Papaxoinis
Georgia Gourgioti
Thomas Makatsoris
Georgia Raptou
Eleni Vrettou
Joseph Sgouros
Epaminontas Samantas
George Basdanis
Pavlos Papakostas
Dimitrios Bafaloukos
Vassiliki Kotoula
Haralambos P. Kalofonos
Chrisoula D. Scopa
George Pentheroudakis
George Fountzilas
机构：
[1] “Hippokration” Hospital,Oncology Section, Second Department of Internal Medicine
[2] Aristotle University of Thessaloniki School of Medicine,Department of Medical Oncology, “Papageorgiou” Hospital
[3] Section of Biostatistics,Division of Oncology, Department of Medicine
[4] Hellenic Cooperative Oncology Group,Department of Pathology
[5] Data Office,Third Department of Medical Oncology
[6] University Hospital,First Propaedeutic Department of Surgery, “AHEPA” Hospital
[7] University of Patras Medical School,Department of Medical Oncology
[8] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[9] “Agii Anargiri” Cancer Hospital,Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research
[10] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[11] “Hippokration” Hospital,Department of Medical Oncology
[12] “Metropolitan” Hospital,undefined
[13] Aristotle University of Thessaloniki School of Medicine,undefined
[14] University Hospital,undefined
[15] University of Patras Medical School,undefined
[16] Ioannina University Hospital,undefined
来源：
BMC Cancer | / 15卷
关键词：
Colorectal cancer; Adjuvant chemotherapy; Modified FOLFOX6; Capecitabine; Oxaliplatin; Prognosis; KRAS; Microsatellite instability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial
    Zhiyu Chen
    Weijian Guo
    Junning Cao
    Fangfang Lv
    Wen Zhang
    Lixin Qiu
    Wenhua Li
    Dongmei Ji
    Sheng Zhang
    Zuguang Xia
    Jiachen Wang
    Jin Li
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 547 - 557
  • [42] Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients
    Chen, Hong-Hwa
    Chen, William Tzu-Liang
    Lee, Hsin-Chung
    Lin, Jen-Kou
    Fang, Chuan-Yin
    Chou, Yenn-Hwei
    Lin, Peng-Chan
    Lin, Bo-Wen
    Huang, Chi-Chou
    Yeh, Chung-Hung
    Hsu, Hsi-Hsien
    Chen, Hung-Chang
    Ting, Wen-Chien
    Yang, Ming-Chin
    Tan, Elise Chia-Hui
    QUALITY OF LIFE RESEARCH, 2015, 24 (02) : 473 - 484
  • [43] Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial
    Chen, Zhiyu
    Guo, Weijian
    Cao, Junning
    Lv, Fangfang
    Zhang, Wen
    Qiu, Lixin
    Li, Wenhua
    Ji, Dongmei
    Zhang, Sheng
    Xia, Zuguang
    Wang, Jiachen
    Li, Jin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 547 - 557
  • [44] Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients
    Hong-Hwa Chen
    William Tzu-Liang Chen
    Hsin-Chung Lee
    Jen-Kou Lin
    Chuan-Yin Fang
    Yenn-Hwei Chou
    Peng-Chan Lin
    Bo-Wen Lin
    Chi-Chou Huang
    Chung-Hung Yeh
    Hsi-Hsien Hsu
    Hung-Chang Chen
    Wen-Chien Ting
    Ming-Chin Yang
    Elise Chia-Hui Tan
    Quality of Life Research, 2015, 24 : 473 - 484
  • [45] Randomized phase II study of tegafur–uracil/leucovorin versus tegafur–uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial)
    Chihiro Kosugi
    Keiji Koda
    Nobuhiro Takiguchi
    Satoru Takaishi
    Hideaki Miyauchi
    Nobuo Hirayama
    Yukihiro Nomura
    Eisuke Kondo
    Yohei Kawasaki
    Yoshihito Ozawa
    Hisahiro Matsubara
    International Journal of Colorectal Disease, 2021, 36 : 1739 - 1749
  • [46] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Nikol Snoeren
    Emile E Voest
    Andre M Bergman
    Otilia Dalesio
    Henk M Verheul
    Rob AEM Tollenaar
    Joost RM van der Sijp
    Sander B Schouten
    Inne HM Borel Rinkes
    R van Hillegersberg
    BMC Cancer, 10
  • [47] Capecitabine Plus Oxaliplatin (XelOx) Compared With Fluorouracil/Folinic Acid ss Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
    Kubicka, Stefan
    STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 (07) : 505 - 506
  • [48] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Snoeren, Nikol
    Voest, Emile E.
    Bergman, Andre M.
    Dalesio, Otilia
    Verheul, Henk M.
    Tollenaar, Rob A. E. M.
    van der Sijp, Joost R. M.
    Schouten, Sander B.
    Rinkes, Inne H. M. Borel
    van Hillegersberg, R.
    BMC CANCER, 2010, 10
  • [49] A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial.
    Takahashi, Takao
    Sunami, Eiji
    Kusumoto, Tetsuya
    Ota, Mitsuyoshi
    Sakamoto, Yoshiyuki
    Tomita, Naohiro
    Maeda, Atsuyuki
    Tejima, Jin
    Okabe, Michio
    Tanaka, Chihiro
    Yamauchi, Junichiro
    Itabashi, Michio
    Kotake, Kenjiro
    Takahashi, Keiichi
    Baba, Hideo
    Boku, Narikazu
    Aiba, Keisuke
    Ishiguro, Megumi
    Morita, Satoshi
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [50] Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201-An updated survival analysis.
    Nimeiri, Halla Sayed
    Feng, Yang
    Catalano, Paul J.
    Meropol, Neal J.
    Giantonio, Bruce J.
    Sigurdson, Elin R.
    Martenson, James A.
    Whitehead, Robert P.
    Sinicrope, Frank A.
    Mayer, Robert J.
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345